Kintara Therapeutics (KTRA) - Long-Term Liabilities to Capital

This historical price chart illustrates the dynamics of Kintara Therapeutics (KTRA), whose long-term debt-to-equity ratio is 0.21. Kintara Therapeutics (KTRA) optimizes late-stage molecule testing through contract research organizations (CRO). The business focuses on developing treatments for resistant gastrointestinal and brain neoplasms, diversifying risks across various research stages. The success of the therapy is driven by close collaboration with specialized clinics to assist critically ill patients.

This indicator assesses the degree of the company's reliance on long-term debt financing relative to its equity. By analyzing the long-term debt structure relative to equity, an investor determines solvency stability during extended investment cycles. The metric is sensitive to any changes in the credit portfolio exceeding one year. This is critical for Kintara Therapeutics (KTRA), as costly clinical trials for oncology drugs require stable long-term funding. Patent protection of intellectual property provides the foundation for servicing such obligations.